CD52 and primary cutaneous T-cell non-Hodgkin lymphoma: Most Trm data stem from mouse studies, but direct evidence for human Trm cells was also provided in a study that examined T cell abundance in a cohort of cutaneous T cell lymphoma (CTCL) patients that received low dose alemtuzumab (anti-CD52 antibody) treatment [31].